Methods for treating degenerative diseases/injuries

Patent metadata

Field	Value
Publication number	US-2016287560-A1
Application number	US-201615182001-A
Country	US
Kind code	A1
Filing date	Jun 14, 2016
Priority date	Apr 29, 2003
Publication date	Oct 6, 2016
Grant date	—

Abstract

Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.

First claim

What is claimed is:

1 . An in vitro or ex vivo method of enhancing the differentation of t lood components in human fetal cord blood into functional cells which method comprises the addition of an effective amount of a non-peptide TPO receptor agonist selected from:
3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and 3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl, or a pharmaceutically acceptable salt thereof; to a culture medium containing human fetal cord blood; followed by optional isolation of the functional cells.

2 . The method of claim 1 wherein progenitor cells are enhanced.

3 . A method of transfusing human fetal cord blood which method comprises the addition of an effective amount of a non-peptide TPO receptor agonist selected from:
3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid, or a pharmaceutically acceptable salt thereof, and 3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl, or a pharmaceutically acceptable salt thereof; to a patient receiving human fetal cord blood.

Assignees

• Novartis Ag

Inventors

• Erickson-Miller Connie L
• Jenkins Julian

Classifications

• A61K31/415

  1,2-Diazoles · CPC title

• C12N5/0602

  Vertebrate cells · CPC title

• A61K31/4152 Primary

  having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone · CPC title

• C12N5/067

  Hepatocytes · CPC title

• A61K31/41

  having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title